Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO and NEW YORK, September 17, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today ahead of the European Society for Medical Oncology (ESMO) Congress 2021 that XTANDI®...
TOKYO, September 14, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on September 1, passed away on September 9...
TOKYO, OSAKA, and IWATE, September 2nd, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ), Nitto Denko Corporation (TSE: 6988, President; Hideo Takasaki, “Nitto”), and M. Heart Co., Ltd. (President and CEO: Yoshimi...
TOKYO, September 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients...
TOKYO, August 31, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D.) today announced that the personnel changes as below...
Follow us
